Keywords: prostrakan, licenses, renal, drugs, amgen, 150m, deal

ProStrakan licenses renal drugs to Amgen in $150M deal

Article | 17 July 2006

Galashiels, Scotland-based ProStrakan Group has exclusively licensed its preclinical renal drug candidates to USA-based Amgen, the world's largest biotechnology company.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Amgen

Go to company listing